vs
Bowman Consulting Group Ltd.（BWMN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Bowman Consulting Group Ltd.的1.6倍（$207.3M vs $129.0M），Bowman Consulting Group Ltd.净利率更高（1.5% vs -62.0%，领先63.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 13.9%），Bowman Consulting Group Ltd.自由现金流更多（$8.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 16.6%）
SLR咨询是一家私有的国际可持续发展咨询企业，在欧洲、北美洲、南美洲、大洋洲及非洲均设有办事处。公司以「推动可持续发展落地」为宗旨，凭借遍布全球的专业顾问与技术团队，携手客户共同应对全球最复杂的各类可持续发展挑战。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BWMN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $129.0M | $207.3M |
| 净利润 | $2.0M | $-128.6M |
| 毛利率 | 55.0% | — |
| 营业利润率 | 3.2% | -54.7% |
| 净利率 | 1.5% | -62.0% |
| 营收同比 | 13.9% | 25.9% |
| 净利润同比 | -66.7% | 3.5% |
| 每股收益（稀释后） | $0.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $129.0M | $207.3M | ||
| Q3 25 | $126.0M | $159.9M | ||
| Q2 25 | $122.1M | $166.5M | ||
| Q1 25 | $112.9M | $139.3M | ||
| Q4 24 | $113.2M | $164.6M | ||
| Q3 24 | $113.9M | $139.5M | ||
| Q2 24 | $104.5M | $147.0M | ||
| Q1 24 | $94.9M | $108.8M |
| Q4 25 | $2.0M | $-128.6M | ||
| Q3 25 | $6.6M | $-180.4M | ||
| Q2 25 | $6.0M | $-115.0M | ||
| Q1 25 | $-1.7M | $-151.1M | ||
| Q4 24 | $5.9M | $-133.2M | ||
| Q3 24 | $771.0K | $-133.5M | ||
| Q2 24 | $-2.1M | $-131.6M | ||
| Q1 24 | $-1.6M | $-170.7M |
| Q4 25 | 55.0% | — | ||
| Q3 25 | 53.1% | — | ||
| Q2 25 | 53.7% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 53.2% | — | ||
| Q3 24 | 52.4% | — | ||
| Q2 24 | 52.5% | — | ||
| Q1 24 | 50.6% | — |
| Q4 25 | 3.2% | -54.7% | ||
| Q3 25 | 4.2% | -106.9% | ||
| Q2 25 | 7.4% | -64.8% | ||
| Q1 25 | 1.0% | -102.6% | ||
| Q4 24 | 1.2% | -74.3% | ||
| Q3 24 | 0.4% | -94.6% | ||
| Q2 24 | -1.2% | -79.1% | ||
| Q1 24 | -2.8% | -151.9% |
| Q4 25 | 1.5% | -62.0% | ||
| Q3 25 | 5.3% | -112.8% | ||
| Q2 25 | 4.9% | -69.0% | ||
| Q1 25 | -1.5% | -108.5% | ||
| Q4 24 | 5.2% | -80.9% | ||
| Q3 24 | 0.7% | -95.7% | ||
| Q2 24 | -2.0% | -89.5% | ||
| Q1 24 | -1.6% | -156.8% |
| Q4 25 | $0.13 | $-1.28 | ||
| Q3 25 | $0.37 | $-1.81 | ||
| Q2 25 | $0.34 | $-1.17 | ||
| Q1 25 | $-0.11 | $-1.57 | ||
| Q4 24 | $0.37 | $-1.34 | ||
| Q3 24 | $0.04 | $-1.40 | ||
| Q2 24 | $-0.13 | $-1.52 | ||
| Q1 24 | $-0.11 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.1M | $421.0M |
| 总债务越低越好 | $57.6M | — |
| 股东权益账面价值 | $261.1M | $-80.0M |
| 总资产 | $579.7M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
| Q4 25 | $11.1M | $421.0M | ||
| Q3 25 | $16.2M | $202.5M | ||
| Q2 25 | $15.5M | $176.3M | ||
| Q1 25 | $10.7M | $127.1M | ||
| Q4 24 | $6.7M | $174.0M | ||
| Q3 24 | $11.7M | $150.6M | ||
| Q2 24 | $23.1M | $480.7M | ||
| Q1 24 | $11.7M | $112.3M |
| Q4 25 | $57.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $32.0M | — | ||
| Q1 25 | $36.4M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $36.4M | — | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $26.8M | — |
| Q4 25 | $261.1M | $-80.0M | ||
| Q3 25 | $261.8M | $9.2M | ||
| Q2 25 | $249.6M | $151.3M | ||
| Q1 25 | $244.1M | $144.2M | ||
| Q4 24 | $246.1M | $255.0M | ||
| Q3 24 | $243.2M | $346.8M | ||
| Q2 24 | $235.6M | $432.4M | ||
| Q1 24 | $167.3M | $140.3M |
| Q4 25 | $579.7M | $1.5B | ||
| Q3 25 | $510.2M | $1.2B | ||
| Q2 25 | $538.2M | $1.3B | ||
| Q1 25 | $528.7M | $1.3B | ||
| Q4 24 | $505.9M | $1.5B | ||
| Q3 24 | $497.0M | $1.5B | ||
| Q2 24 | $463.4M | $1.6B | ||
| Q1 24 | $420.5M | $1.3B |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $8.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 6.3% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.76× | — |
| 过去12个月自由现金流最近4个季度 | $33.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $9.4M | $-99.8M | ||
| Q3 25 | $10.2M | $-91.4M | ||
| Q2 25 | $4.3M | $-108.3M | ||
| Q1 25 | $12.0M | $-166.5M | ||
| Q4 24 | $11.9M | $-79.3M | ||
| Q3 24 | $6.8M | $-67.0M | ||
| Q2 24 | $3.1M | $-77.0M | ||
| Q1 24 | $2.5M | $-190.7M |
| Q4 25 | $8.1M | $-100.8M | ||
| Q3 25 | $10.1M | $-92.7M | ||
| Q2 25 | $4.2M | $-110.7M | ||
| Q1 25 | $11.0M | $-167.8M | ||
| Q4 24 | $11.7M | $-79.5M | ||
| Q3 24 | $6.6M | $-68.6M | ||
| Q2 24 | $2.7M | $-79.0M | ||
| Q1 24 | $2.3M | $-193.9M |
| Q4 25 | 6.3% | -48.6% | ||
| Q3 25 | 8.0% | -58.0% | ||
| Q2 25 | 3.4% | -66.5% | ||
| Q1 25 | 9.7% | -120.5% | ||
| Q4 24 | 10.4% | -48.3% | ||
| Q3 24 | 5.8% | -49.2% | ||
| Q2 24 | 2.6% | -53.7% | ||
| Q1 24 | 2.4% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.9% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.3% | 1.4% | ||
| Q1 24 | 0.3% | 3.0% |
| Q4 25 | 4.76× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.02× | — | ||
| Q3 24 | 8.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BWMN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
